Accepted for Publication: May 17, 2022.
Published: July 13, 2022. doi:10.1001/jamanetworkopen.2022.21616
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Di Chiara C et al. JAMA Network Open.
Corresponding Author: Costanza Di Chiara, MD, Division of Pediatric Infectious Diseases, Department for Women’s and Children’s Health, University of Padua, Via Giustiniani 3, Padua, Italy (firstname.lastname@example.org).
Author Contributions: Drs Giaquinto and Di Chiara had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Padoan and Prof Giaquinto contributed as co–last authors.
Concept and design: Di Chiara, Cantarutti, Costenaro, Donà, Palma, Di Salvo, De Rossi, Giaquinto.
Acquisition, analysis, or interpretation of data: Di Chiara, Cantarutti, Costenaro, Bonfante, Cosma, Ferrarese, Cozzani, Petrara, Carmona, Liberati, Palma, Plebani, Padoan.
Drafting of the manuscript: Di Chiara, Cantarutti, Costenaro, Cosma, Ferrarese, Liberati, Padoan.
Critical revision of the manuscript for important intellectual content: Cantarutti, Costenaro, Donà, Bonfante, Cozzani, Petrara, Carmona, Palma, Di Salvo, De Rossi, Plebani, Padoan, Giaquinto.
Statistical analysis: Cantarutti, Costenaro, Padoan.
Obtained funding: Palma, Giaquinto.
Administrative, technical, or material support: Di Chiara, Bonfante, Cosma, Cozzani, Petrara, Carmona, Liberati, Palma.
Supervision: Costenaro, Donà, Palma, Di Salvo, De Rossi, Plebani, Padoan, Giaquinto.
Conflict of Interest Disclosures: Dr Palma reported receiving grants from the Chiesi Foundation to support research about immunologic aspects of long-term COVID-19 in children outside the submitted work. No other disclosures were reported.
Funding/Support: This work was partially supported by ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic). ORCHESTRA has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement 101016167.
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The submission for publication was discussed with the funder.
L , Zhang
W , Hu
et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. [published correction appears in JAMA. 2020 Aug 4;324(5):519]. JAMA
. 2020;324(5):460-470. doi:10.1001/jama.2020.10044
L , Segovia-Chumbez
B , Jadi
et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol
. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413
Q , Zhang
Y , Lian
et al. Chemiluminescence immunoassay based serological immunoassays for detection of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent patients and vaccinated population. Viruses
. 2021;13(8):13. doi:10.3390/v13081508
MS , Hansen
CB , Kristiansen
et al. SARS-CoV-2 natural antibody response persists for at least 12 months in a nationwide study from the Faroe Islands. Open Forum Infect Dis
. 2021;8(8):ofab378. doi:10.1093/ofid/ofab378
V , Srichatrapimuk
S , Manopwisedjaroen
et al. SARS-CoV-2 neutralizing antibodies decline over one year and patients with severe COVID-19 pneumonia display a unique cytokine profile. Int J Infect Dis
. 2021;112:227-234. doi:10.1016/j.ijid.2021.09.021
European Centre for Disease Prevention and Control. Reinfection With SARS-CoV-2: Implementation of a Surveillance Case Definition Within the EU/EEA. ECDC; 2021.
G , Jeffery-Smith
A , Zambon
et al. Antibody persistence and neutralising activity in primary school students and staff: prospective active surveillance, June to December 2020, England. EClinicalMedicine
. 2021;41:101150. doi:10.1016/j.eclinm.2021.101150
P , Alanio
C , Hammer
et al; Milieu Intérieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med
. 2018;10(1):59. doi:10.1186/s13073-018-0568-8
H , López-Martínez
B , Parra-Ortega
et al. Analysis of the behaviour of immunoglobulin G antibodies in children and adults convalescing from severe acute respiratory syndrome-coronavirus-2 infection. Front Pediatr
. 2021;9(9):671831. doi:10.3389/fped.2021.671831
M , Terpos
E , Ntanasis-Stathopoulos
et al. Sequential analysis of binding and neutralizing antibody in COVID-19 convalescent patients at 14 months after SARS-CoV-2 infection. Front Immunol
. 2021;12:793953. doi:10.3389/fimmu.2021.793953
MR , Bonfante
F , Costenaro
et al. Asymptomatic and mild SARS-CoV-2 infections elicit lower immune activation and higher specific neutralizing antibodies in children than in adults. Front Immunol
. 2021;12:741796. doi:10.3389/fimmu.2021.741796
J , Dowell
AC , Pearce
et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. [published correction appears in Nat Immunol. 2021 Jul;22(7):928]. Nat Immunol
. 2021;22(5):620-626. doi:10.1038/s41590-021-00902-8